In pancreatic cancer cells treated with GEM, we observed that compared with the control group, P53 and BAX protein expressions were significantly up-regulated, while BCL2 protein levels were down regulated (p < 0.05). This evidence concerns the gene BCL2 and familial pancreatic carcinoma.